GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zim Laboratories Ltd (NSE:ZIMLAB) » Definitions » 3-Year EPS without NRI Growth Rate

Zim Laboratories (NSE:ZIMLAB) 3-Year EPS without NRI Growth Rate : 16.30% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Zim Laboratories 3-Year EPS without NRI Growth Rate?

Zim Laboratories's EPS without NRI for the three months ended in Dec. 2024 was ₹0.82.

During the past 12 months, Zim Laboratories's average EPS without NRI Growth Rate was -6.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 16.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Zim Laboratories was 95.70% per year. The lowest was -44.80% per year. And the median was 11.80% per year.


Competitive Comparison of Zim Laboratories's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's 3-Year EPS without NRI Growth Rate falls into.


;
;

Zim Laboratories 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Zim Laboratories  (NSE:ZIMLAB) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Zim Laboratories 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Zim Laboratories's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zim Laboratories Business Description

Traded in Other Exchanges
Address
Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is a pharmaceutical company. The company is mainly engaged in the manufacturing of formulation drugs and pre-formulation ingredients. Geographically, the group has a business presence in India and other countries, of which key revenue is derived from Outside India. The products offered by the company are Ondansetron, Melatonin, Nicotine, Vitamin D3, and others. The majority of its revenue is derived from the sale of pharmaceutical goods.

Zim Laboratories Headlines

No Headlines